-Business Standard Domestic regulators need to be stricter about quality violations to protect both Indian pharma exports as well as the country's image Even as major Indian drug companies continue to make news for impurities in the medicines they make and faulty - or if the USFDA is to be believed, falsified - data that many generate after testing of samples show quality problem, it seems strange that domestic authorities are silent...

-The Telegraph Regulators in several European countries are suspending marketing approval for 25 generic drugs because of concerns over the quality of data from human studies conducted by an Indian contract research company, a French medical safety agency said on Friday. Drug regulators in Belgium, France, Germany and Luxembourg have decided to suspend the marketing authorisation for the generic drugs after they discovered "irregularities" in documents relating to human studies conducted by...

-The Hindu Consent does not matter, says study A majority of parents who get their children married before the legal age do not even seek their consent, and among those who do, the child not consenting does not stop the marriage, new data has shown. In 2011, the Planning Commission selected the G.B. Pant Institute of Studies in Rural Development, Lucknow, for a study on child marriage in India. The 2005-06 National Family...

-The Hindu Silicosis deaths in Rajasthan mines leave behind a trail of young widows The Karauli-Dholpur-Bharatpur mining belt in eastern Rajasthan, which produces the country's best quality red sandstone, also has the largest number of young widows, most of them below 40 years. The older ones were widowed some decades ago, and worse, young girls almost see their future unfold before them. The common link: they were married to miners who died of...

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...